23 November 2023Big PharmaLiz Hockley
EPO revokes Moderna's COVID-19 vaccine patent
The European Patent Office hands a win to BioNTech and Pfizer in coronavirus vaccine dispute | US biotech plans to appeal decision affecting mRNA patent.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
29 August 2023 Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.
Big Pharma
30 May 2023 A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue.
Editor's picks
Editor's picks
Big Pharma
30 May 2023 A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue.
Big Pharma
29 August 2023 Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.
Big Pharma
30 May 2023 A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue.
Big Pharma
29 August 2023 Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.